Search

Displaying results 2841 - 2850 of 9670 in total
  1. Drug

    Metixene

    go.drugbank.com/drugs/DB00340
    Approved

    Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.

  2. Drug

    Metrizamide

    go.drugbank.com/drugs/DB01578
    Experimental

    It is also used as a resorbable, non-ionic contrast medium.

  3. Drug

    Cipepofol

    go.drugbank.com/drugs/DB16295
    ApprovedInvestigational

    [L63809] Haisco describes it as the first China-originated innovative intravenous anesthetic to enter the global market. … Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated

  4. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. … [A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women.

  5. Drug

    Chloramphenicol succinate

    go.drugbank.com/drugs/DB07565
    Approved

    [L14174] Chloramphenicol succinate was granted FDA approval on 20 February 1959.[L12711] … [A204065] Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias.

  6. Drug

    Benzylpenicilloyl polylysine

    go.drugbank.com/drugs/DB00895
    ApprovedInvestigational

    Benzylpenicilloyl polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy.

  7. Drug

    Amcinonide

    go.drugbank.com/drugs/DB00288
    Approved

    Amcinonide is a corticosteroid.

  8. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.

  9. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme

  10. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    It is the morpholinoethyl ester of niflumic acid [L1496]. In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with bronchitis showed improvement [A7889].